STOCK TITAN

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

BOSTON and LAUSANNE, Switzerland, June 15, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), today announced that the Company has published its first Environmental, Social and Governance Impact Summary ("ESG Impact Summary"). The ESG Impact Summary highlights the Company's policies, ongoing practices, and recent initiatives across a range of areas including innovation and access, protecting patient data, empowering its people, as well as other key priority areas. The ESG Impact Summary is available on SOPHiAGENETICS.COM, in the Investor Relations section.

"We are thrilled to be taking the first steps in SOPHiA GENETICS' ESG journey. We place patient care at the heart of all our decisions. Our success is deeply rooted in our core values and the positive impact we have in the ESG areas across all levels of the organization. This is critical to our mission of creating a wiser and more sustainable healthcare system," said Dr. Jurgi Camblong, Co-Founder and CEO at SOPHiA GENETICS.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers. 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-publishes-environmental-social-and-governance-impact-summary-301568678.html

SOURCE SOPHiA GENETICS

SOPHiA Genetics SA

NASDAQ:SOPH

SOPH Rankings

SOPH Latest News

SOPH Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing

About SOPH

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based